Laure Buisson

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy

Marianne Weulersse, Assia Asrir, Andrea Pichler et al. · Immunity · 2020 · 139 citations · Full text

Life Sciences, Immunology, Oncology +14

Multiple myeloma clonal evolution in homogeneously treated patients

Jill Corre, Alice Cleynen, Sébastien Robiou du Pont et al. · Leukemia · 2018 · 125 citations · Full text

Medicine, Hematology, Oncology +12

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow

Céline Mazzotti, Laure Buisson, Sabrina Mahéo et al. · Blood Advances · 2018 · 90 citations · Full text

Medicine, Hematology, Oncology +16

del(17p) without <i>TP53</i> mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Jill Corre, Aurore Perrot, Denis Caillot et al. · Blood · 2020 · 87 citations · Full text

Medicine, Genetics, Oncology +12

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot et al. · Blood · 2022 · 62 citations · Full text

Medicine, Hematology, Oncology +8